Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
Miplyffa (arimoclomol), an oral medication for Neimann-Pick disease, type C (NPC). Miplyffa, in combination with Johnson & ...
New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...
New Jersey Business23h
Tris Pharma Promotes Naidu to Chief Commercial Officer
Tris Pharma, Inc. (Tris) has announced the promotion of Manesh Naidu, MBA, to chief commercial officer. Naidu previously ...
oncnursingnews23h
NKT2152 Shows Promising Efficacy in Advanced Clear Cell Kidney Cancer
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive ...
Indiatimes19h
Novartis India Share Price
Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,650.43 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...